Ethyl (2E)-3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-2-propenoate

説明Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist developed by Shionogi for improvement of thrombocytopenia associated with chronic liver disease in patients undergoing an elective invasive procedure (e.g., liver biopsy, liver transplantation). Thrombocytopenia, which is common among patients with chronic liver disease, increases the risk of bleeding when undergoing invasive procedures, which in turn complicates therapy and increases the risk of mortality. Lusutrombopag, which was approved in Japan in September 2015, promotes platelet production by stimulating the proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes via the thrombopoietic pathway. The consequent increase in platelet levels avoids postponement of invasive procedures or transfusion of platelets and administration of platelet products, the current standard of care for thrombocytopenia in these patients.